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INTRODUCTION 
INTRODUCTION 
Barrett’s oesophagus is a condition in which an abnormal columnar 
epithelium that is predisposed to malignancy replaces the stratified squamous 
epithelium that normally lines the distal oesophagus. Barrett’s oesophagus is a 
consequence of chronic gastro-oesophageal reflux disease. The prevalence is 
between 2 to 7% in the adult population. It is a risk factor for development of 
dysplasia and later adenocarcinoma. The risk of malignancy is approximately 
0.5% per year increasing to 4-6% with high grade dysplasia. Majority of these 
individuals with metaplasia, dysplasia and early adenocarcinoma are 
asymptomatic. 
Diagnosis is by endoscopy and biopsy confirmation of intestinal 
metaplasia. Routine white light endoscopy and biopsy identifies long segment 
Barrett’s oesophagus with good accuracy. Short segment Barrett’s, foci of 
dysplasia and early adenocarcinoma can easily be missed on routine white light 
endoscopy and biopsy. Identifying dysplasia and malignancy at an early stage is 
very important in decreasing the morbidity, mortality and improves treatment 
outcomes. Considering the increased risk of malignancy and better outcome 
with early diagnosis, various new techniques have been developed to improve 
the early detection. 
Chromoendoscopy refers to the topical application of stains or dyes at the 
time of endoscopy in an effort to enhance tissue characterization, differentiation 
or diagnosis. It enhances detection of dysplasia and early cancer of G.I tract, 
especially in patients with pre-malignant conditions and those with high risk of 
developing cancer. It is a valuable tool for early detection of Barrett’s 
metaplasia, dysplasia and adenocarcinoma.  
Among the various stains used methylene blue C.E is the most common 
technique used for identifying Barrett’s epithelium. Various studies have 
highlighted the usefulness of methylene blue C.E in Barrett’s metaplasia and 
dysplasia. However there are mixed reports from studies regarding the accuracy 
of this technique. 
We conducted this study in our department to evaluate and compare the 
efficacy of methylene blue directed biopsy in early detection of Barrett’s 
metaplasia, dysplasia and early adenocarcinoma in high risk population 
compared to random biopsy. 
 
 
 
 
  
 
 
 
 
REVIEWOF LITERATURE 
REVIEW OF LITERATURE 
 
HISTORICAL PERSPECTIVE : 
 The term Barrett’s oesophagus is coined after Norman Barrett, who first 
described the condition in 1950. He first described a case of chronic peptic ulcer 
in the mucosa of the distal oesophagus lined by epithelium
2
. It is also referred to 
as Barrett’s syndrome or columnar lined lower oesophagus. The original initial 
description was related to congenital short oesophagus with intra thoracic 
gastric columnar lining. After three years, anatomical reason for the occurrence 
of columnar lining in the distal esophagus as an acquired condition seen in 
patients with chronic gastro-oesophageal reflux was provided by Allison
3
. 
Subsequently the association with gastro-oesophageal reflux was confirmed by 
several studies
4
.  
The development of a columnar lined oesophagus as an adaptive response 
to gastro-oesophageal reflux was demonstrated in animal studies subsequently 
in several studies
5
. As per histology the adaptive response includes, junctional 
type epithelium, gastric fundic type epithelium and a distinctive intestinal 
metaplasia
6
. Subsequent studies described the association of columnar lined 
oesophagus with risk of cancer
7
. Considering the malignant potential and the 
need to eliminate confusion between the type of epithelium, columnar lined 
oesophagus of 3cm length was needed to make a diagnosis
8
. Later studies 
highlighted the fact that it was intestinal metaplasia that had malignant potential 
and not the fundic type epithelium.
9
Hence it is appropriate to make a diagnosis 
after endoscopic visualization and histological confirmation of intestinal 
metaplasia.
10
 
DEFINITION : 
―In 1998 the American college of gastroenterology defined Barrett’s 
oesophagus as a change in the epithelium of the distal oesophagus of any length 
that can be detected at endoscopy and confirmed to have intestinal metaplasia 
by biopsy and excludes metaplasia of the cardia‖.11 
 ―The British society of gastroenterology defines Barrett’s oesophagus as 
any portion of the normal squamous lining replaced by macroscopically visible 
columnar epithelium and histologically confirmed intestinal metaplasia.‖ 
 
CLASSIFICATION OF BARRETT’S OESOPHAGUS : 
Earlier studies recommended a minimum length of 3cm of columnar lined 
oesophagus from the GEJ for defining Barrett’s oesophagus.8 Subsequent 
studies revealed that even lesions (<3cm) with intestinal metaplasia were 
associated with malignant potential . Hence it was classified further into two 
types based on the length of columnar lined oesophagus. Barrett’s oesophagus is 
categorized into two types, long segment and short segment. Long segment 
Barrett’s also called traditional Barrett’s oesophagus refers to 
metaplasticcolumnar epithelium extending at least 3cm above the 
gastroesophageal junction (GEJ) and short segment < 3cm above the GEJ.
1
 
Prague Criteria ForCategorizing Barrett’s: 
There has been significant inter and intra-observer variability when it 
comes to classifying long and short segment Barrett’s oesophagus among 
endoscopist worldwide.
12
Several studies have shown that increase in length of 
columnar metaplasia is associated with a doubling of risk of adenocarcinoma.  
Considering the increased malignant potential with increasing length of 
Barrett’s metaplasia and significant inter-observer variability among 
endoscopist in identifying these lesions a validated, simple method to categorize 
Barrett’s was required. 
 Hence the International working group on classification of oesophagitis 
came up with a new criteria in 2002. In  Prague criteria C stands for 
circumferential extent and M stands for maximal extent of the suspected 
columnar metaplasia from the GEJ, identified as proximal extent of gastric 
mucosal folds (figure 1).
13
 
The criteria was named Prague as it was presented first at Prague in 
September 2004. The criteria were found to be simple, reliable and easy to 
apply. However its clinical significance especially for identifying short 
segment’s Barrett’s remains inconclusive. 
                      Figure 1: The Prague criteria (C and M criteria) 
An alternative proposal was to use descriptive terms like oesophagus 
lined by columnar epithelium and to segregate based on the presence or absence 
of intestinal metaplasia, as per the modified Savary-Miller grading of 
oesophagitis. Using the above system grades range from 0 to 4, based on the 
extent of CLO and presence of intestinal metaplasia.
14 
EPIDEMIOLOGY : 
The condition is commonly found in older individuals above the fifth 
decade during upper gastrointestinal endoscopy as a part of evaluation of 
chronic GERD.
15
The most common age group at diagnosis is the 6
th
 to 7
th
 
decade, with a median age being approximately 55yrs. There is a sharp rise in 
the diagnosis of Barrett’s metaplasia over the age of 40-50yrs.16 In contrast the 
prevalence is rare in children below the age of 10yrs and almost never seen 
below the age of 5yrs.
17
 
The median incidence of Barrett’s esophagus is 1.17%.18There is an 
increase in the incidence of Barrett’s paralleling the increase in incidence of 
GERD. Among adults with symptoms of GERD lesions more than 3cm is found 
in 3% to 5 % and short segment in 10% to 20% during endoscopy.
1
Overall the 
prevalence is 1.6% to 6.8%.
19 
In most series white Caucasian men are found to 
have the highest incidence of Barrett’s metaplasia and the condition being 
uncommon in Asians and black Africans. Among men and women the 
prevalence is significantly more among men with an estimate of 65% affected 
being male population. 
RISK FACTORS : 
Gastro-esophageal reflux disease is the most important among various 
predisposing factors studied. Barrett’s oesophagus arises as a result of chronic 
mucosal damage of the distal oesophagus due to chronic gastro-oesophageal 
acid reflux. This finding has been validated in several studies and meta-
analysis.
20
 Individuals with central obesity are strongly predisposed to GERD, 
Barrett’s and its associated complications.21The proposed mechanism being, 
increase in intra-abdominal pressure leading predisposing to GERD. 
Various studies have been conducted to study the association with 
lifestyle factors. Among the lifestyle factors cigarette smoking is found to 
increase the risk of Barrett’s oesophagus modestly, whereas there seems to be 
no significant association with alcohol consumption.
22
 Aspirin, various NSAIDs 
and Helicobacter pylori infection appear to decrease the risk of having these 
lesions.  
RISK OF MALIGNANCY : 
Barrett’s metaplasia is a premalignant condition, predisposing to the 
development of adenocarcinoma. It has been found that 0.5% of individuals 
with simple Barrett’s are likely to develop a malignant lesion in a calendar 
year.
23 
It has also been found that around 4.3% and 0.9% of these individuals are 
likely to develop low-grade and high-grade dysplasia respectively in a year. A 
thorough analysis has found that the risk of developing malignancy in 
individuals with dysplasia ranges from 0.6% for low grade lesions and 4% to 
6% in a year for high-grade lesions.
24
 
PATHOGENESIS : 
Barrett’s oesophagus or columnar lined oesophagus is the end result of 
chronic severe gastro-oesophageal reflux disease. There are multiple 
physiological abnormalities in these individuals that puts them at the risk for 
severe gastro-oesophageal reflux disease. The proposed physiologic 
mechanisms contributing to GERD in patients with Barrett’s oesophagus are 
extreme lower oesophageal sphincter hypotension, ineffective oesophageal 
motility, hiatus hernia, gastric acid hyper secretion, duodenogastric reflux, 
decreased salivary secretion of epidermal growth factor (EGF) and decreased 
oesophageal pain sensitivity. The above physiological abnormalities either alone 
or in combination have potential consequences which ultimately lead to 
oesophageal mucosal injury and columnar metaplasia.  
Transient lower oesophageal sphincter relaxation (tLESR): 
tLESRs represent LES relaxation independent of swallowing. It is 
prolonged, associated with relaxation of crural diaphragm and not associated 
with oesophageal peristalsis.
25
60 to 70% of reflux episodes in GERD is 
secondary to this mechanism.
26
 
Hypotensive lower oesophageal sphincter: 
LES hypotension results in gastro-oesophageal reflux either strain-
induced or free relux.
27
 Strain induced reflux occurs when LES pressure is 
greater than 10mm hg, whereas free reflux usually occurs when LES pressure is 
less than 5mm hg. The reason for LES hypotension is obscure. Presence of 
hiatus hernia reduces the LES pressure due to loss of intrinsic crural 
diaphragmatic support.
27
Several studies have shown association of hypotensive 
LES with oesophagitis. 
Hiatus hernia: 
In patients with hiatus hernia the LES is displaced proximally into the 
chest, especially the high pressure zone.It impairs LES pressure mainly by 
reducing the LES pressure and to a certain extent by impairing the oesophageal 
acid clearance.
28,29
  Hiatus hernia increases reflux episodes and is associated 
with complications like oesophagitis, stricturing and BE.
28
The incidence of 
hiatus hernia in patients with oesophagitis is 54% to 94%, and this association 
has been proven in two studies.
29,30
 
Oesophageal acid clearance: 
There are two mechanisms, namely  
1. Volume clearance  
2. Acid clearance  
The normal oesophagus has two types of normal peristaltic waves (primary and 
secondary). Studies have shown that the normal oesophagus would be able to 
clear a 15 ml fluid bolus by means of primary peristalsis.
31
Peristaltic 
dysfunction is associated with increasing severity of oesophagitis. In a study 
done in Chicago it was found that oesophagealdysmotility was more prevalent 
in patients with severe oesophagitis, around 50%.
32
 
Salivary secretion has been found to play a role in oesophageal acid 
clearance by clearing the remnant acid from the oesophagus after the peristaltic 
wave.
31
 Stimulated salivation by sweeteners significantly reduces acid clearance 
time, whereas decreased salivation prolongs clearance.
33
 Studies have shown an 
impaired oesophagosalivary reflux in these individuals.
34
 
Gastric factors : 
The factors associated with GERD and its sequelae are gastric acid hyper 
secretion, duodenogastric reflux and delayed gastric emptying. Studies have 
found that when the frequency and duration of acid and bile reflux is high to an 
extent of pH <4, the severity of oesophageal injury is significantly high.
3536
 
Further it has been shown in several studies that apart from acid, bile 
reflux also plays a significant role in oesophageal injury. In a study it was found 
that bile reflux, especially reflux occurring in the recumbent position was 
strongly associated with oesophageal mucosal injury and columnar lined 
oesophagus.
88
 
COLUMNAR METAPLASIA : 
Barrett’s oesophagus or columnar metaplasia of the distal oesophagus 
occurs secondary to long standing GER. Columnar Metaplasia occurs as a result 
of the pathology described so far. The pathology is more pronounced in patients 
with long segment than short segment Barrett’s oesophagus. But some studies 
showed normal acid secretion in patients with long segment Barrett’s and 
another study suggesting short segment Barrett’s occurs in 5% of adults without 
association of GERD.
37,38
 Columnar metaplasia occurs as a protective repair 
mechanism to chronic oesophageal injury.  
The progenitor cell of origin for Barrett’s metaplasia is not clearly 
known. The hypothesis put forward are 
1. Abnormal differentiation of multipotent stem cells in the basal layer of 
oesophagus into columnar cells after GERD induced damage to squamous 
epithelium and exposure to gastric juice.  
2. Differentiation of stem cells in ducts of oesophagealsubmucosal glands 
and bone marrow stem cells.
39
 
Varoius studies have shown the expression of certain genes is also 
important in the pathogenesis. The genes identified are Cdx genes and bone 
morphogenetic protein (BMP)-4, both of which are known to mediate 
differentiation of intestinal type columnar cells.
40 
These genes are over-
expressed in the squamous epithelium of patients with reflux oesophagitis. 
CARCINOGENESIS : 
Barrett’s epithelial cells are more resistant to acid injury due to the 
property of mucin secretion and expression of tight-junction protein called 
claudin 18. However, it is predisposed to malignancy. Carcinogenesis occurs in 
a stepwise manner through low-grade dysplasia, high-grade dysplasia and 
adenocarcinoma.  
Progression  to Malignancy 
 
Squamous epithelium 
 
Oesophagitis 
 
Columnar Metaplasia 
 
Low grade dysplasia 
 
High grade dysplasia 
 
Malignancy 
 
Carcinogenesis occurs as a result of accumulation of series of genetic and 
epigenetic alterations. These alterations include self-sufficiency in growth 
signals due to expression of oncogenes (cyclin D1, K-ras), growth factors (TGF-
α), EGFR and insensitivity to anti-growth signals (TP53 and p16 
inactivation).
41
Neovascularization and ability to invade and metastasize is 
achieved by expression of VEGF and MMPs.
22
 Numerous genetic instability 
have been detected in metaplastic cells at risk of cancer. Among them 
Aneuploidy detected by flow cytometry and FISH is a potential biomarker of 
neoplasia. 
42
 
CLINICAL FEATURES: 
Barrett’s oesophagus per se does not produce any characteristic clinical 
manifestations. Usually they will manifest features of chronic GERD. The 
clinical features of GERD are classified as oesophageal and extra-oesophageal. 
They are as listed below. 
1. Heart burn: 
It is a classic symptom of GERD, described as burning    sensation rising 
from the lower chest or stomach and radiating to the neck or throat. 
43
 It 
usually occurs postprandially and worsened by bending or supine posture. 
As a predominant symptom it has a specificity of (89%) and sensitivity of 
(38%) for GERD.
44
Heart burn for 2 or more days a week is usually 
diagnostic of GERD. 
2. Acid regurgitation: 
Effortless regurgitation of acidic fluid especially after meals and 
worsened by supine posture and bending forward is highly suggestive of 
GERD.
44 
Daily regurgitation is associated with LES hypotension 
3. Less common symptoms are  
 Water brash,  
 Odynophagia,  
 Burping,  
 Hiccups, nausea, and vomiting,  
 Hematemesis and  
 Dysphagia. 
4. Extra-oesophageal symptoms :  
Patients can present with noncardiac chest pain, asthma, reflux laryngitis, 
recurrent pneumonitis and dental erosions.
45
 Numerous studies have 
shown that GER is the most common oesophageal cause of noncardiac 
chest pain.
46
 GERD is seen in 34% to 89% of asthmatics. GERD should 
be considered in adult onset asthma without an atopic component.
47
It is 
one of the leading causes of chronic cough. 
COMPLICATIONS OF GERD 
Complications secondary to GERD have decreased significantly in the 
PPI era, especially non-cancer related complications. Some of the complications 
likely to occur and deserve attention are hemorrhagic oesophagitis, aspiration 
pneumonia, and oesophageal rupture with severe oesophagitis, peptic stricture 
and Barrett’s oesophagus. Upper Gastro Intestinal bleed is seen in 7-18%.48 
Peptic strictures are reported in 7% to 23% of untreated patients.
49
 
 
COMPLICATIONS OF BARRETT’S OESOPHAGUS  
Benign complications:  
 Oesophagitis, Stricture formation, Ulceration and rarely Perforation. 
Oesophagitis: It has been shown in various studies 60 to 70% are found 
to have inflammation macroscopically, and on microscopy it is found in 
most patients. Inflammation is found in the more proximal segments. 
Persistent inflammation predisposes to stricture formation. 
Stricture: Various studies have shown that strictures occur in around 20-
40% of individuals and is seen more often near the squamo-columnar 
junction. 
Ulceration: Ulceration in the columnarized segment has been reported to 
occur (2- 45%) in various studies. They can be asymptomatic or present 
with complications like bleeding (upto 50%) and rarely perforation.  
Malignant complications: 
 Low grade dysplasia 
 High grade dysplasia and 
 Malignancy – Barrett’s predisposes to the development of 
adenocarcinoma of distal oesophagus. 
The main concern with Barrett’s metaplasia is its malignant potential. 
The overall incidence being 0.5% per year.
23
 Low-grade and high-grade 
dysplasia develops at 4.3% and 0.9% per year respectively. A patient with 
Barrett’s low grade and high-grade dysplasia have a  0.6% and 4 to 6% per year 
risk of malignancy.
24
 
Since 1970’s there has been a significant rise in the incidence of 
adenocarcinoma of the distal oesophagus. It has also been found in one of the 
studies that only 5% of individuals with malignancy were diagnosed to have 
BE, showing the ineffectiveness of available routine screening techniques 
(Dulai et al).
87
 Dysphagia or development of alarm symptoms should alert to the 
possibility of malignancy. 
DIAGNOSIS 
There are 2 criteria for diagnosis of BE. They are endoscopy and 
histopathological examination. 
ENDOSCOPY IN DIAGNOSIS : To make a diagnosis of columnar lined 
oesophagus on endoscopy one should first be aware of important anatomical 
landmarks, like the anatomical GEJ (proximal extent of gastric mucosal folds), 
the Z line or squamo-columnar junction and appearance of columnar 
epithelium.
50
Endoscopically, columnar epithelium has a reddish colour and 
velvet like texture, which is readily distinguished from the pale and glossy 
squamous epithelium. (Figure: 1) 
The  diagnosis of long segment Barrett’s can be done with reasonable 
accuracy, while lesions < 3 cm can be easily missed.
51
 At endoscopy diagnosis 
is made by measuring the extent of columnar lining from GEJ proximally. As 
the columnar lining can be circumferential, tongue like projection or islands, the 
Prague criteria is used to describe the circumferential and maximum extent.
13
 In 
a large scale endoscopic study the sensitivity and specificity for diagnosing 
CLO was 82% and 81% but significantly low for short segment disease.
52 
 
Figure 1: Shows the reddish, velvety columnar mucosa of Barrett’s 
oesophagus 
The next important role of endoscopy is to biopsy the columnar lined 
oesophagus. The most important role of oesophageal biopsy in patients with 
GERD is to determine the presence of Barrett’s epithelium.53The protocols 
regarding site of biopsy, number of biopsies have been confusing. Studies have 
shown 4 quadrant biopsies at 2cm intervals may improve accuracy but data are 
lacking.
54
Overall routine white light endoscopy can identify long segment CLO 
with reasonable accuracy, with sensitivity dropping drastically for short 
segment CLO, stressing the need for alternative methods to endoscopically 
diagnose CLO.
52
 
PATHOLOGY IN DIAGNOSIS : 
Barrett’s oesophagus occurs as a response to convert the compromised 
squamous epithelium to glandular epithelium which can resist acid induced 
tissue damage. The columnar lined epithelium can show three subtypes, namely 
cardiac type, fundic type and intestinal type.
55
Among these the intestinal type 
mucosa has characteristic villiform pattern with profound incomplete 
morphological and histochemical properties and is considered to be 
pathognomic of Barrett’s metaplasia.56 
 Immunohistochemistry has demonstrated small intestinal type protein 
villin and cytokeratin histochemistry shows oesophageal specificity.
57,58
 Lot of 
research has gone into identifying the type of epithelium required to confirm 
columnar metaplasia. It is now required to identify intestinal type of columnar 
metaplasia with goblet cells and native oesophageal structures in juxtaposition 
in the biopsy specimen to make a definitive diagnosis of Barrett’s oesophagus. 
(Figure 2) 
 
Figure 2 : Shows normal squamous epithelium (arrow head), juxtaposed 
with metaplastic columnar epithelium containing intestinal type goblet cells 
Subsequently studies found that by using these criteria a definitive 
diagnosis can be made in only 10% to 15% of biopsies studied. In a multi-centre 
study conducted by United Kingdom Barrett’s oesophagus registry only 15% of 
biopsies were found to have native oesophageal structures.
59
Hence the British 
Society of Gastroenterology guidelines suggests that ―histological correlation of 
endoscopically visible columnarisation results in highest diagnostic accuracy‖.  
The guidelines also recommend that the reporting of diagnostic biopsies 
be done as Biopsies diagnostic of CLO, Biopsies corroborative of endoscopic 
diagnosis, Biopsies in keeping with, but not specific for CLO and Biopsies with 
no evidence of CLO. 
NEW ENDOSCOPIC MODALITIES : 
Barrett’s oesophagus is considered a premalignant condition. Regular 
endoscopic surveillance is recommended to diagnose early malignancy.
60 
Barrett’s mucosa is heterogenous in that areas of metaplasia, dysplasia and foci 
of early malignancy can occur simultaneously, making it difficult to distinguish 
with routine endoscopy and biopsy.
61
  As discussed above routine white light 
endoscopy can easily miss short segment Barrett’s, areas of dysplasia and early 
adenocarcinoma, thereby stressing the need for alternative  methods to 
endoscopically diagnose CLO. New developments which have shown lot of 
promise are discussed below.
52
 
CHROMOENDOSCOPY : 
―Chromoendoscopy, or chromoscopy, refers to the topical application of 
stains or dyes at the time of endoscopy in an effort to enhance tissue 
localization,characterization, differentiation, or diagnosis‖.62 It enhances  
detection of dysplasia, early cancer of G.I tract and has clinical application in a 
wide range of conditions including Barrett’s oesophagus. The stains or dyes 
used are classified based on their mechanism of action as absorptive, contrast 
and reactive stains. Absorptive stains are used in study of Barrett’s oesophagus. 
Among absorptive stains, methylene blue is most commonly used in detection 
of Barrett’s metaplasia, associated dysplasia and cancer.63 
METHYLENE BLUE CHROMOENDOSCOPY : 
Most commonly used in the diagnosis of BE and its complications.
63
 The 
mechanism is absorption of Methylene blue and staining of epithelium of small 
bowel, colon and intestinal metaplasia of oesophagus dark blue (Canto et al).
64 
Whereas dysplasia and carcinoma show heterogenous or absent staining.
65
 
Methylene blue directed biopsy has a sensitivity of (32 to 98%) and specificity 
of (23 to 100%).  
PROCEDURE : 
Materials required : 
1. Methylene blue (liquid formulation) – 0.5% strength 
2. Spray catheter – 7 Fr 
3. Biopsy forceps 
Technique : 
 The patient first undergoes a white light endoscopy 
 The area to be stained is rinsed using normal saline or N-acetyl cysteine 
vigorously to remove excess mucous attached to the mucosa 
 Then a Spray catheter is introduced through the working channel 
 5 to 10ml of Methylene Blue 0.5% is sprayed across the area of interest 
starting from squamo-columnar junction 
 After two to three minutes, the excess dye is washed using normal saline 
 10 minutes later, staining pattern is noted and targeted biopsies taken. 
SPRAY CATHETER : 
The most important step in doing chromoendoscopy is staining of the 
area of interest. Proper and uniform circumferential staining is required, so that 
targeted biopsies can be taken, thus improving the yield of the procedure. This 
cannot be achieved using a regular catheter or cannula. Hence the need for an 
ideal catheter. 
The spray catheter has at its tip, numerous fine porous openings, which 
sprays the solution in the form of a fine uniform mist at a certain pressure, 
resulting in uniform homogenous staining, thus making the procedure simple 
and easy (Figure 3 & 4). 
Dimensions : 
1. Size : 7 Fr,  
2. Catheter Length – 240 cm, Stylet length – 100cm,  
3. Catheter tip – spray and 
4. Minimum accessory channel – 2.8 mm 
 
Figure 3 : Spray catheter used in our study 
 
Figure 4 : Depicts fine,uniform and circular spraying of dye using spray catheter 
 Ragunath K, Krasner et al in a randomized control trial published in 2003 
reported a statistically significant increased detection rate for Barrett’s 
metaplasia using methylene blue chromoendoscopy directed biopsy in 
comparison to white light endoscopy and random biopsy.
66
 
Similarly John David Horwhat et al in a randomized control trial 
published in 2008 found that using methylene blue chromoendoscopy lesser 
number of biopsies were required to diagnose Barrett’s metaplasia and 
dysplasia. They also reported that methylene blue chromoendoscopy helped to 
define areas to target for biopsy.
85
Increased detection of dysplasia and cancer in 
Barrett’s oesophagus has also been demonstrated in studies.65 
The main disadvantage with methylene blue chromoendoscopy is the 
differences in staining technique, inter and intra-observer variability in 
interpreting staining pattern as reported by Meining A et al.
67
 Overall methylene 
blue C.E has better detection rate and is inexpensive, relatively easy to perform 
with minimal side effects.  
Various other new endoscopic modalities have been developed to 
improve detection of metaplasia, dysplasia and cancer. They will be discussed 
in brief as follows.  
High Resolution Endoscopy (HRE): These are endoscopes with mechanically 
and electronically moveable lens at the distal tip of variable focal length, which 
can be zoomed in and out at areas of interest without compromise of image 
quality. Sharma et al has described areas of high grade dysplasia to have 
irregular mucosal pattern on HRE.
68 
Various studies have also shown the 
efficacy of HRE in detecting intestinal metaplasia.
69
 Finally HRE when 
combined with chromoscopy increases the yield significantly. 
Narrow Band Imaging (NBI): 
 The NBI system has a standard high definition mode and in addition an 
NBI mode where an interference filter is used to illuminate the area of interest 
using narrowed red, blue and green filters, with a relative increase in blue filter 
bandwidth. By the above mechanism, different images at different levels of 
mucosa are seen, with an increase in contrast between epithelium and 
underlying vasculature. The end result is image and mucosal characterization of 
high resolution without the need of chromoscopy.
70
 
Autofluorescence Imaging (AFI): 
In AFI certain molecules called fluorospore when excited or stimulated 
by ultraviolet light; emit fluorescent light spreadover a range of longer 
wavelengths from the green to thered spectrum. The composition of 
fluorospores in dysplastic and metaplastic epithelium is different and hence 
have different autofluorescence spectra compared to normal epithelium. Many 
studies have reported good results in distinguishing non-dysplastic from 
dysplastic and cancerous tissue in Barrett’s oesophagus.71 AFI results are 
affected by tissue morphology and it samples only a small area, hence needs 
further validation. 
Some of the other modalities which have shown promise are optical 
coherence tomography (OCT) and light scattering spectroscopy. 
MANAGEMENT : 
Management includes treatment per se and surveillance. The decision to 
treat, the type of treatment and the ideal surveillance strategies differ from one 
individual to another. It also depends on the extent of lesion and the presence or 
absence of dysplasia. Treatment of Barrett’s oesophagus includes medical (acid 
suppression), endoscopic therapy and surgery. 
A. Treatment of Non-dysplastic Barrett’s: 
1. Acid suppression: Treatment of GERD in patients with Barrett’s 
oesophagus does not differ much from that in the general population, 
except that it is recommended to maintain therapy with a PPI even in the 
absence of symptoms. The reason for this  approach is based on the 
evidence that persistent exposure to acid promotes carcinogenesis.
72
For 
individuals with no adequate clinical or endoscopic response it is 
recommended to increase the dose of PPI by four times or the maximum 
recommended dose. Both American college of gastroenterology and 
British society of gastroenterology recommend use of PPI at a dose that 
controls GERD symptoms and heals oesophagitis. 
2. Antireflux surgery: The role of fundoplication in Barrett’s oesophagus 
is similar to GERD in the general population at present. A meta-analysis 
conducted by Mayo clinic showed that competent fundoplication reduced 
the need for PPI and also reduced the risk of adenocarcinoma.
73
But a 
meta-analysis by Corey et al did not show statistical significance.
74
 At 
present it is recommended not to do fundoplication for the sole purpose of 
cancer prevention. 
3. Endoscopic Ablation: Endotherapy is a useful therapeutic tool which 
removes the metaplastic epithelium and leads to regeneration of 
squamous epithelium.
75
Endotherapy is of two types namely thermal and 
non-thermal. Among the various ablative modalities RFA gives the best 
results. The problem at present is the persistence of rests of glandular 
metaplasia underneath the neo-squamous epithelium.
76
At this juncture 
ablative therapy as a single modality is not recommended for non-
dysplastic Barrett’s. 
B. Management of Low-grade Dysplasia:   
Diagnosis of low-grade dysplasia in Barrett’s CLO first needs to be 
confirmed with a repeat biopsy after 8 to 12 weeks of aggressive PPI therapy as 
presence of oesophagitis can result in false positive diagnosis.
77
If repeat biopsy 
confirms the diagnosis then management is similar to non-dysplastic Barrett’s 
CLO. Regular surveillance at 6month or 1 year interval until regression and then 
every 2 to 3 years is recommended.
78
 
C. Management of High-grade Dysplasia: 
Diagnosis of high grade dysplasia needs a repeat confirmation by an 
expert pathologist. Treatment should be individualized. Individualization is 
based on age, comorbidities and life expectancy. Treatment options include 
endotherapy and surgery. Young, healthy individual with verified  high-grade 
dysplasia is best treated with esophagectomy,
79
 whereas for an elderly, infirm 
individual with comorbidities, endotherapy is best suited.
80
 For short segment 
CLO, Endoscopic mucosal resection (EMR) followed by PPI and for long 
segment Barrett’s, EMR followed by RFA is recommended.81 
SURVEILLANCE: 
Barrett’s oesophagus is a pre-malignant condition, with risk of cancer 
being 0.5% per year, with risk increasing to 0.6% with low grade dysplasia and 
4% to 6% with high grade dysplasia. Considering the increased risk and good 
treatment outcomes with early detection of malignancy, it is important to have 
regular surveillance programs. Surveillance protocols differ according to 
whether an individual has non-dysplastic or dysplastic Barrett’s oesophagus. 
The guidelines put forward by various societies are discussed below. 
 
Non-dysplastic Barrett’s: 
In an individual with Barrett’s metaplasia without dysplasia, verified on 2 
consecutive endoscopy and biopsy, the American college of Gastroenterology 
guidelines recommends surveillance endoscopy and four quadrant biopsy at 
three year intervals.
82
 The British Society of Gastroenterology guidelines on the 
other hand recommend surveillance endoscopy with four quadrant biopsy and 
biopsy of any suspicious lesion once in two years.
83,84
 Among the two the 
American guidelines is the most widely accepted and followed. 
Dysplastic Barrett’s: 
If low-grade dysplasia is identified on biopsy from CLO, both the 
American and British society of gastroenterology recommend a repeat 
endoscopy and quadrantic biopsy after 8 to 12 weeks of PPI therapy. The repeat 
biopsy needs careful evaluation by an experienced pathologist for evidence of 
dysplasia and any foci of invasive carcinoma. If the repeat endoscopy and 
biopsy is positive for low-grade dysplasia, then the American college of 
gastroenterology recommends surveillance endoscopy and quadrantic biopsy 
plus biopsy of any new lesion at one year interval,
82
 while the British society 
recommends endoscopy and four quadrant biopsy every 6 months.
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AIM OF THE STUDY 
AIM OF THE STUDY 
 To evaluate and compare the efficacy of methylene blue 
chromoendoscopy inthe detection of Barrett’s metaplasia, 
Dysplasia & early esophageal adenocarcinoma in high risk 
population compared to routine random biopsy. 
 
 
 
 
  
 
MATERIALS AND 
METHODS 
MATERIALS AND METHODS 
This is a hospital based prospective cohort study, done at Department Of 
Digestive Health and Sciences, Government Peripheral hospital, Anna nagar, 
Chennai from April 2013 to February 2014. A total of 50 patients were selected 
for the study using the inclusion criteria. 
INCLUSION CRITERIA: 
1. Chronic Gastro-oesophageal reflux disease 
2. Chronic smoking 
3. Chronic Alcohol intake 
4. Obesity 
EXCLUSION CRITERIA: 
1. Oesophageal candidiasis 
2. Oesophageal varies 
3. Hypersensitivity / allergy to drugs 
4. Prior H/o oesophageal malignancy 
5. H/o endoscopic therapy 
6. NSAID intake  
7. Pregnancy  
 
 
METHODOLOGY:  
50 patients were selected based on the inclusion and exclusion criteria 
 A detailed history was taken and physical examination done for all the 
patients 
 Complete blood count, renal parameters and random blood sugars were 
checked for all patients 
 Written and informed consent was obtained from all the patients prior to 
the procedure 
 White light video oesophago-gastroduodenoscopy was done and random 
four quadrant biopsy was taken from columnar appearing and suspicious 
lesions of  the distal oesophagus 
Technique of staining : 
 Spray catheter is introduced through the working channel. The area to be 
stained is washed with normal saline.  
 Then  0.5 % methylene blue, 5 ml to 10ml was sprayed over the areas of 
interest distal to proximal starting from the OGJ. A vigorous saline rinse 
was done to remove the excess dye. 
 After 10 minutes, a repeat VOGD was done, staining pattern was 
observed and targeted biopsies were taken as per staining pattern. 
 Biopsy material was sent for histopathological examination using routine 
Haematoxylin, eosin and Alcian blue staining to look for evidence of Barrett’s 
metaplasia, dysplasia and adenocarcinoma. 
 Results were assessed and compared for the detection of Barrett’s 
metaplasia, dysplasia and adenocarcinoma. 
Materials required : 
1. Methylene blue (liquid formulation) – 0.5% strength 
2. Spray catheter – 7 Fr, 240cm, minimal accessory channel of 2.8 mm 
3. Biopsy forceps 
 
 
Methylene Blue  (0.5%) from Merc specialities used 
in the study 
SPRAY CATHETER USED IN THE STUDY 
Dimensions : 
1. Size : 7 Fr,  
2. Catheter Length – 240 cm, Stylet length – 100cm,  
3. Catheter tip – spray and 
4. Minimum accessory channel – 2.8 mm 
 
 
                                Spray catheter used in the study 
  
 
RESULTS AND ANALYSIS 
RESULTS AND STATISTICAL ANALYSIS 
A total of 50 patients were included for the study based on inclusion 
criteria. All patients had atleast one feature of Chronic GERD 
Statistical analysis was done using SPSS software (Version 19). 
Univariate and Multivariate analysis was done. Z test for proportion was used to 
compare histology results of the two study arms. 
AGE DISTRIBUTION : Among the 50 patients included in our study, most of 
the patients were middle aged with 18 (36%) in the 6
th
 decade followed by 28% 
in the 5
th
 and 22% in the 7
th
 decade. (Table 1, Figure 1) 
Age groups Number of subjects Percentage 
21 – 30 3 6 
31 – 40 4 8 
41 – 50 14 28 
51 – 60 18 36 
61 – 70 11 22 
Total 50 100 
 
Table  1: Shows the age distribution of subjects 
 
 
 
 
GENDER DISTRIBUTION: 
Among the 50 patients in our study 40 (80%) were males and 10 (20%) 
were females. (Table 2, Figure 2) 
Table 2: Gender Distribution 
Gender Number of subjects Percentage 
Male 40 80 
Female 10 20 
Total 50 100 
 
 
 
 
Figure 2: Depicts gender distribution. 40 (80%) were male patients 
PRESENTING COMPLAINTS: In our study most of the patients presented 
with clinical features of GERD. Among which Heartburn (n=40), and 
Regurgitation (n=31) were the most common presentation. 11 (22%) also had 
nocturnal symptoms. All the patients had atleast 1 symptom of GERD, with 
many having more than two features of GERD. (Table 3; Figure 3) 
Table 3: Shows presenting features of study population 
Presentation Number of subjects Percentage  
Heart burn 40 80% 
Regurgitation  31 62% 
Non-cardiac 
chest pain 
8 16% 
Vomiting  5 10% 
Nocturnal 
symptoms 
11 22% 
 
 
Figure 3: Shows the clinical presentation in the study population. 
RISK FACTORS: 
In our study all 50 patients had chronic GERD. Among the other risk factors 
smoking was seen in 28 (56%), Alcohol intake was seen in 12 (24%) and 
Obesity in 8 (16%). Patients either had a single or combination of risk factors. 
(Table 4; Figure 4) 
Table 4 : Shows the risk factors seen in the study population 
Risk Factors Number of 
Subjects 
Percentage  
Chronic GERD 50 100% 
Obesity  8 16% 
Smoking  28 56% 
Alcohol  12 24% 
 
  
Figure 4: Depicts the risk factors and their prevalence in the study 
population 
METHYLENE BLUE STAINING PATTERN: 
In our study the presence of homogenous dark blue staining was 
considered uniform pattern and heterogenous staining was classified as patchy 
staining pattern. Out of the 50 patients studied 11(22%) had uniform staining 
pattern , 35 (70%) had patchy staining and 4 had absent staining. (Figure 5, 6& 
7).  
Table5 : Shows the staining pattern and their frequency 
Staining pattern Number of subjects Percentage  
Uniform staining 11 22% 
Patchy staining 35 70% 
Absent  4 8% 
 
 
Figure 5 : Depicts the staining pattern in the study population 
DIFFERENT STAINING PATTERNS 
 
Figure 6: Depicts uniform staining pattern in a patient with 
Barrett’s
 
Figure 7 : Depicts patchy staining 
NUMBER OF BIOPSIES : 
In our study, a total of 189 biopsies were taken from areas of interest in 
the random biopsy arm and 139 biopsies in the methylene blue 
chromoendoscopy arm. The average number of biopsies taken in the random 
biopsy arm was 4 and number of biopsies taken in the MBDB arm was 3. 
The reason for decreased number of biopsies required in the MBDB arm can be 
explained by the targeting of the biopsies to the well stained areas highlighted 
by methylene blue. (Table 6; Figure 8) 
Table 6: Shows the total and average number of biopsies in each arm 
Biopsy type Total number  Average number  
Random biopsy 189 3.78 
MBDB 139 2.78 
 
 
Figure 8 : Shows the average number of biopsies taken in each arm 
Correlation between Staining pattern and Study end points: 
Among 50 patients, 5 patients were diagnosed to have Barrett’s 
metaplasia in the methylene blue chromoendoscopy arm. Out of these 5 patients 
4 had uniform staining and 1 had patchy staining pattern. (Figure 6) 
Out of the 50 patients 2 patients were diagnosed to have low-grade 
dysplasia. Out of these 2 patients 1had uniform and 1 had patchy staining. 
(Figure 9) 
Patients with Barrett’s metaplasia were more likely to have uniform 
staining. However the above findings did not have any statistical significance. 
 
 
Figure 9: Shows staining pattern in patients with Barrett’s & dysplasia 
HISTOPATHOLOGY: 
 In our study overall 5 (10%)patients were diagnosed to have Barrett’s 
metaplasia using methylene blue chromoendoscopy, whereas only 2 (6%) 
patients were diagnosed to have Barrett’s using random biopsy. 3 out 5 with 
Barrett’s were found to have non-specific changes in the Random Biopsy group. 
The 2 arms of the study were comparable for detection of gastric metaplasia and 
Oesophagitis. 
Figure 10 : Depicts Histological Correlation between the 2 study arms. 
MBDB – Methylene Blue Directed Biopsy 
 
 
 
 
Z TEST FOR PROPORTIONS  
a. Barrett’s : 6% of subjects were diagnosed with Barrett’s in white light 
endoscopy  - random biopsy, whereas 10% of subjects were diagnosed 
with Barrett’s in methylene blue chromoendoscopy, but the difference is 
not statistically significant;  (Z is -0.7372, p value – 0.459) 
b. Dysplasia : 0% of subjects were diagnosed with Dysplastic changes in 
white light endoscopy  - random biopsy, whereas 4% of subjects were 
diagnosed with dysplastic changes in methylene blue chromoendoscopy, 
but the difference is not statistically significant; (Z is – 1.4286, p value – 
0.153) 
 
 
 
 
  
 
DISCUSSION 
DISCUSSION 
Barrett’s oesophagus represents an adaptive response of the mucosal 
lining of the distal oesophagus to the injurious effect of acid refluxing from the 
stomach over a prolonged period of time. Various studies have come up with 
different definitions for Barrett’s. At present the definition which is accepted 
and followed is the ACGE definition in 1998. ACGE definition requires 
endoscopically proven change in the epithelial type and histological 
confirmation of intestinal metaplasia.
11 
The condition derives its importance because of its malignant potential. 
BE predisposes to the development of adenocarcinoma and this risk is found to 
correlate directly with the extent of lesion and the presence of dysplastic foci.
12
 
Since 1970’s there has been a significant rise in the incidence of 
adenocarcinoma of the distal oesophagus. It has also been found in one of the 
studies that only 5% of individuals with malignancy were diagnosed to have 
BE, showing the ineffectiveness of available routine screening techniques 
(Dulai et al).
87
 
Hence, it is important to make an early and definitive diagnosis of 
Barrett’s oesophagus in high-risk groups. Routine white light endoscopy and 
biopsy is the commonly used screening technique. The diagnosis of lesions 
lesions>3cm can be done with reasonable accuracy, but easily misses smaller 
lesions and dysplastic foci (Sharma et al).
51
Hence the need for alternative 
methods to endoscopically diagnose CLO.  
In our study we have compared the efficacy of routine endoscopy and 
biopsy with methylene blue chromoendoscopy for detection of Barrett’s 
oesophagus and its complications. 
AGE GROUP : 
In most of the studies in literature the most common age group at 
diagnosis is 6
th
 and 7
th
 decades, with a median age being approximately 55years. 
Studies have also found a significant increase in diagnosis above the 5
th
 decade. 
( Bonelli L et al)
16
 
In our study 43(86%) out of 50 patients were above the 5
th
 decade, with 
36% found in the 6
th
 decade. Out of the 5 patients diagnosed to have Barrett’s 
oesophagus 1 patient was in the 6
th
 decade, 2 each in the 5
th
 and 7
th
 decade.  The 
age distribution in our study is similar to other studies in literature. 
GENDER : 
Most studies of the studies done in patients having chronic GERD for 
diagnosis of  BE have found a male predominance. In most of the studies 65 -75 
% of the patients are male (Cameron AJ et al).
87
In a study by Van Blankenstein 
et al
88
 a male to female ratio of four is to one was observed. 
In our study 40 (80%) patients were male. This predominance of male sex 
in our study is in accordance with most studies in literature. 
PREDISPOSING FACTORS : 
Among predisposing factors studied, chronic gastro-oesophageal reflux is 
the most important. There appears to be linear correlation between increase in 
GERD prevalence and Barrett’s. This finding has been validated in many 
studies and meta-analysis (Singh P; Taylor RH et al).
20
 Among other factors 
central obesity is strongly associated (Hampel et al)
21
 and smoking increases the 
risk modestly.
22
 
In our study all 50 patients had features of Chronic GERD. Chronic 
smoking was present in 28(56%), Alcohol consumption in 12(24%) and obesity 
in 8(16%). Out of the 5 patients with Barrett’s all had features of GERD, 3 
patients were obese and 3 had smoking and alcohol consumption.  
The result for GERD in our study is comparable to studies in literature 
(Singh P et al). The relationship for other predisposing factors does not correlate 
well with other studies. 
STAINING PATTERN : 
There was controversy regarding the staining pattern after methylene blue 
chromoendoscopy among various studies. ASGE guidelines for staining is 
currently used and also followed in our study. Persistent dark blue staining is 
considered positive for metaplasia (Canto et al)
64
 and heterogenous or absent 
staining suggestive of dysplasia or malignancy .
65
 
In our study 11 out of 50 patients had uniform dark blue staining and 35 
patients had patchy staining. Out of 5 patients with BE in our study, 4 patients 
had uniform staining and 1 had patchy staining. Out of 2 patients with dysplasia 
1 each had uniform and patchy staining. The staining pattern for Barrett’s 
oesophagus in our study is in accordance with studies in literature (Ragunath K, 
Krasner et al).
66
 
NUMBER OF BIOPSIES : 
Most studies on the efficacy of MBCE in the diagnosis of barrett’s have 
shown that the number of biopsies required in the chromoendoscopy arm was 
significantly less compared to the routine endoscopy and random biopsy arm. 
In a randomized control trial by John David Howard et al  published in 
2008 it was found that using methylene blue chromoendoscopy lesser number of 
biopsies were required to diagnose Barrett’s metaplasia and dysplasia. 
In our study, the total number of biopsies required were 189 and 139 in 
the random biopsy and MBDB arm respectively. The average number of 
biopsies required were 4 and 3 in random biopsy and MBDB arm respectively. 
This is in accordance with most studies in literature. 
 
PREVALENCE : 
The prevalence  of BE worldwide is not exactly known because around 
one-third of these patients are asymptomatic(Gerson et al).
86
 Overall prevalence 
in the western population ranges from 2 to 7%, with a slightly decreased 
prevalence in the Asians.(Ronkainen J et al)
19
 
In a study by Punia RS et al
89
 in the Indian population  the prevalence 
was found to be 23.6%, out of 55 patients with Chronic GERD. This high 
prevalence could attributed to the inclusion of  gastric metaplasia n making a 
diagnosis. 
In our study the 6% detection rate of BE in random biopsy arm is similar 
to the overall prevalence worldwide, while the 10% detection rate in MBDB 
arm is higher than worldwide prevalence. This increase in detection rate in the 
MBDB arm is attributed to well targeted biopsies taken from dark blue stained 
areas. 
Detection of Barrett’s Oesophagus and Dysplasia:  
Most studies on the efficiency of methylene blue chromoendoscopy in the 
diagnosis of Barrett’s have shown a significantly better rate of detection for 
chromoendoscopy.  
Ragunath K, Krasner et al in a randomized control trial published in 2003 
reported a statistically significant increased detection rate for Barrett’s 
metaplasia using methylene blue chromoendoscopy directed biopsy in 
comparison to white light endoscopy and random biopsy.
66
 
SimilarlyJohn David Horwhat et al in a randomized control trial 
published in 2008 found that using methylene blue chromoendoscopy lesser 
number of biopsies were required to diagnose Barrett’s metaplasia and 
dysplasia. 
In our study on histopathological examination Barrett’s oesophagus was 
detected in 2 (6%) of patients on random biopsy arm, while 5(10%) were 
diagnosed in the methylene blue chromoendoscopy arm. The increased 
detection rate in the MBDB arm is attributed to targeted biopsies taken from 
dark blue stained areas. MBDB arm detected more cases and the results were in 
accordance with literature
(66,85)
 (Z is 0.7372, P – 0.459) 
In our study low grade dysplasia was not detected in any of the patients in 
the random biopsy arm, while 2 (6%) of biopsies in MBDB arm were positive 
for these lesions. Again MBDB detected cases were routine biopsy was 
negative, and the results are are in accordance with literature (John David 
Horwhat et al)
85
  ( Z is -1.4296, P – 0.153). 
  
 
 
CONCLUSION 
CONCLUSION 
 This study is the first of its kind to be done in South India. 
 In our study Methylene Blue Chromoendoscopy and biopsy diagnosed 
Barrett’s metaplasia to a higher percentage than white light endoscopy 
and routine biopsy in patients with chronic gastro-oesophageal reflux 
disease. 
 Further uniform staining pattern also suggested that the patient was more 
likely to have Barrett’s metaplasia when compared to patchy staining. 
 This procedure is very useful and can be done and reproduced in any 
centre without requirement of any specialized equipment. Hence 
Chromoendoscopy with Methylene blue is a useful tool for early 
detection of Barrett’s oesophagus and thereby suggest appropriate 
treatment and surveillance for oesophageal malignancy. 
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ANNEXURES 
PROFORMA 
 
Name :                         Age/ Sex :                          DDHD No: 
HISTORY: 
Heart Burn :        Chest Pain :               Regurgitation :                Reflux :         
Belching:                        Water brash :                   Odynophagia:                
Nausea/ Vomiting :           Dysphagia :     Hiccughs :                   Early Satiety :                 
Cough :           Wheeze :     Nocturnal symptoms : 
PAST HISTORY 
DM:      SHTN:    PTB :         IHD :        Previous Surgery :   Previous 
endoscopic Therapy :       Drug / NSAID intake :                            
PERSONAL HISTORY:Smoking :                 Alcohol intake :                  
Tobacco :                      Caffine :                    Sleep pattern :            Diet : 
FAMILY HISTORY : G.I Malignancy, Chronic GERD 
 
 
GENERAL EXAMINATION: 
SensoriuPallor:       Icterus :Cyanosis :     Clubbing :Pedaledema: 
Lymphadenopathy : 
Other Signs : 
Height : Weight :                            BMI: 
Pulse :                        Blood pressure :                                     Temp :                        
 
SYSTEMIC EXAMINATION: 
CVS :     RS :         P/A :         CNS :     
INVESTIGATIONS:                                         
Hb :   ESR :       TC :     DC :         Platelets : 
BT :    CT:         Rbs :       Urea :        Creatinine : 
ECG :     Chest X-Ray : 
VOGD Report : 
Methylene Blue Chromoendoscopy : 
HPE Report : 
 
  
MASTER CHART 
 
 
S. NO 
DDHD 
No Age Sex Heartburn Regugitation NCCP Vomiting 
Nocturnal 
symptoms Smoking Alcohol Obesity 
White 
Light 
endoscopy MBCE RB MBDB 
1 3440/12 39 1 1 1 2 2 1 1 1 2 1 1 2 2 
2 6611/13 44 1 1 2 2 2 1 1 1 2 2 1 1 1 
3 7534/13 38 1 2 1 2 2 2 1 2 2 3 2 2 2 
4 6993/13 61 1 1 1 2 2 1 2 1 1 2 1 5 1 
5 4229/13 40 2 1 1 1 2 1 2 2 1 2 2 5 5 
6 6350/13 23 2 2 1 2 2 2 2 2 2 3 2 4 4 
7 4371/13 58 1 2 1 2 2 2 1 2 2 1 2 4 4 
8 5150/13 62 1 1 1 2 2 2 1 1 2 3 2 4 4 
9 4850/13 54 1 1 1 2 2 1 1 2 2 2 2 2 2 
10 2150/12 57 1 1 1 2 2 1 1 2 1 1 1 2 2 
11 5580/13 68 2 2 2 1 2 2 2 2 1 1 2 5 13 
12 5823/13 62 2 1 1 2 2 2 2 2 2 1 2 2 2 
13 708/05 48 1 1 1 2 2 2 1 2 2 3 2 4 4 
14 5783/13 25 2 2 1 2 2 2 2 2 2 3 2 4 4 
15 6042/13 42 2 1 2 2 1 2 2 2 2 2 2 4 5 
16 4796/13 36 1 1 2 2 2 1 2 2 2 1 1 2 2 
17 5817/13 58 1 1 1 2 1 2 1 1 1 1 1 1 1 
18 5549/13 47 2 1 2 2 2 2 2 2 2 2 2 5 5 
19 6264/13 50 2 1 1 2 2 2 2 2 2 3 2 4 4 
20 3410/13 43 1 1 2 2 2 1 2 2 1 1 1 2 2 
21 6375/13 28 2 1 2 2 2 2 2 2 2 3 2 4 4 
22 4722/13 44 1 1 1 2 2 1 1 1 2 1 1 5 13 
23 2778/11 53 1 1 1 2 2 2 1 2 2 1 2 5 2 
24 1272/12 63 1 1 2 2 2 2 2 2 2 2 2 5 5 
25 3767/10 46 1 1 2 2 2 2 1 2 2 3 2 4 4 
26 4254/13 56 1 1 1 2 2 2 1 2 2 3 2 4 4 
27 1243/10 54 1 1 2 2 2 2 1 2 2 2 2 5 2 
 Biopsy : 1- Barrett’s metaplasia, 2 – gastric metaplasia, 3 – dysplasia, 4 – oesophagitis, 5 – non-specific changes 
Staining pattern : 1 – uniform staining, 2 – patchy staining, 3 – absent staining; Other parameters : 1-present, 2 - absent
28 6121/11 49 1 2 1 2 1 2 2 2 2 1 1 2 2 
29 4879/13 58 1 1 2 2 2 2 2 2 2 2 2 5 5 
30 3343/11 51 1 1 2 2 2 2 1 2 2 3 2 2 2 
31 1657/12 59 1 1 1 2 2 2 2 2 1 1 1 2 2 
32 2335/13 57 1 1 1 2 2 2 1 1 2 3 2 4 4 
33 3698/12 60 1 1 2 2 2 2 1 2 2 1 1 5 5 
34 4465/13 47 1 1 1 2 2 2 1 2 2 1 2 5 5 
35 5767/13 65 1 1 2 2 2 2 2 2 2 1 2 2 2 
36 6757/10 45 1 1 2 1 2 2 1 1 2 3 3 5 5 
37 2712/12 55 1 2 1 1 2 2 1 2 2 2 2 5 5 
38 199/14 58 1 1 1 2 2 2 1 2 2 3 2 4 4 
39 307/14 54 1 1 1 2 1 1 1 1 2 1 1 2 2 
40 611/14 66 1 2 1 1 2 2 2 2 2 1 2 4 4 
41 457/10 46 1 1 2 2 2 2 1 1 2 3 3 5 5 
42 1511/11 48 1 1 1 2 2 2 2 1 2 3 2 4 4 
43 5344/13 58 2 1 1 1 1 1 2 2 2 1 2 4 4 
44 731/14 59 1 1 1 2 2 2 1 2 2 2 2 5 5 
45 852/12 61 1 2 2 1 2 2 2 2 2 1 2 2 2 
46 6542/12 67 1 1 1 2 2 2 1 2 1 3 3 5 5 
47 4856/13 42 1 1 1 2 2 2 1 1 2 2 2 4 4 
48 5988/13 62 1 2 2 1 2 2 2 2 2 1 2 2 2 
49 2654/12 53 1 1 2 2 2 2 1 2 2 3 3 5 5 
50 934/10 64 1 1 1 2 2 2 1 2 2 2 2 2 2 
  
